| __timestamp | ADMA Biologics, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 22732000 |
| Thursday, January 1, 2015 | 4311461 | 29245000 |
| Friday, January 1, 2016 | 6360761 | 33206000 |
| Sunday, January 1, 2017 | 29164321 | 31152000 |
| Monday, January 1, 2018 | 42194635 | 10136000 |
| Tuesday, January 1, 2019 | 39504238 | 45546000 |
| Wednesday, January 1, 2020 | 61291426 | 43367000 |
| Friday, January 1, 2021 | 79769341 | 81413000 |
| Saturday, January 1, 2022 | 118814535 | 139304000 |
| Sunday, January 1, 2023 | 169273000 | 192361000 |
| Monday, January 1, 2024 | 159417000 |
Unleashing the power of data
In the ever-evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Halozyme Therapeutics, Inc. and ADMA Biologics, Inc. over the past decade. From 2014 to 2023, both companies have shown significant growth in their cost of revenue, reflecting their expanding operations and market reach.
Halozyme Therapeutics, Inc. saw a remarkable increase of approximately 747% in its cost of revenue, peaking in 2023. Meanwhile, ADMA Biologics, Inc. experienced an even more dramatic rise of around 4,424% during the same period. This surge highlights the aggressive expansion and scaling strategies employed by these companies. As the biotech sector continues to innovate, monitoring these financial metrics provides valuable insights into the operational efficiencies and strategic directions of these industry players.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Walgreens Boots Alliance, Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Pharming Group N.V.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Halozyme Therapeutics, Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.